Compare KTF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTF | ACRS |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 314.2M |
| IPO Year | N/A | 2015 |
| Metric | KTF | ACRS |
|---|---|---|
| Price | $9.17 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 103.3K | ★ 3.1M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.40 | $1.05 |
| 52 Week High | $9.12 | $4.89 |
| Indicator | KTF | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | N/A |
| Support Level | $9.09 | N/A |
| Resistance Level | $9.15 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 100.00 | 0.00 |
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.